Net Margin: Imunon, Inc. (IMNN)

Corporate emblem and logo of Imunon (IMNN)

The net profitability chart helps identify the true profitability trend, with the current level sitting around 0.00. This metric for Imunon, Inc. (IMNN) is based on a unique genetic code delivery system into neoplasms, which ensures a high therapy cost. The business relies on proprietary TheraPlas plasmid platforms that link clinics with proprietary protocols. Development is proceeding organically with the goal of future molecule licensing to pharma behemoths.

Imunon (IMNN) Net Return on Sales: for the period 04/28/2023 - 11/19/2026

Comprehensive metric breakdowns and analytics for Imunon (IMNN)

- share price and expert price forecast:
- company stock exchange capitalization indicators:
Summary company analysis:Celsion Corporation - IMNN
Flagship merchandise of imunon.com

Net profit margin reflects the share of net income in total revenue, measuring the efficiency of converting income into final capital. For Imunon, Inc. (IMNN), this metric characterizes the cost of the DNA platform validation process under strict operational control. By analyzing the net profit margin trend, an investor can discern the real cost of clinical trials. The metric's dynamics confirm management discipline. The long-term consensus is based on the expectation of future data monetization.

Competitor analysis

TEM: Net Sales Margin|Net Profitability Margin Qiagen QGEN|IONS (Isis Pharmaceuticals) - Net Sales Margin|Repligen Inc. - Net Profit Margin|Net Sales Margin RNA|CRSP - Net Margin|GeneDx - Return on Sales by Net Profit|Net Profit Rate RARE|Beam Tx - Net Sales Margin|SRPT - Net Sales Margin|TWST (Twist Bio) - Return on Sales by Net Profit|Net Return on Sales TXG|Return on Sales by Net Profit NTLA|Stoke Therapeutics Inc (STOK) - Company Sales Margin|Net Sales Margin BLFS|Net Margin WVE (Wave Life Sciences Corp)|Net Margin Maze Therapeutics MAZE|Net Profit Rate SION|PRME - Net Margin|Company Sales Margin Taysha TSHA|QURE: Net Sales Margin|Return on Sales by Net Profit MeiraGTx PLC|RGNX (REGENXBIO Inc) - Net Sales Margin|solidbio.com (SLDB) - Company Sales Margin|Net Margin Ocugen Corp (OCGN)|Pacific Biosciences of California, Inc. - Net Return on Sales|Benitec Biopharma - Return on Sales by Net Profit|DSGN: Net Return on Sales|RCKT: Return on Sales by Net Profit|FDMT - Net Sales Margin|LXEO: Net Sales Margin|Korro Bio Inc. - Net Profit Rate|EDIT (editasmedicine.com) - Net Sales Margin|Net Margin SLN|Net Margin ProQR Therapeutics NV (PRQR)|Codexis - Net Return on Sales|Net Margin Sangamo SGMO|NAUT: Net Return on Sales|MGX: Return on Sales by Net Profit|Net Margin Precision BioSciences|GBIO (generationbio.com) - Return on Sales by Net Profit|Net Margin boundlessbio.com (BOLD)|XCUR (exicuretx.com) - Net Sales Margin|Phio Pharmaceuticals - Net Profit Margin|Net Margin Mustang Bio, Inc. (MBIO)|Company Sales Margin TransCode Therapeutics, Inc.|Net Margin Bionano Genomics BNGO|Net Profit Rate APDN|BLUE - Net Margin|Net Profit Margin IPA|Omega Therapeutics, Inc. (OMGA) - Net Margin|Singular Genomics Corp (OMIC) - Net Sales Margin|RGLS (Regulus Therapeutics, Inc.) - Net Sales Margin|SYRS: Net Profit Rate|Return on Sales by Net Profit TBIO (Telesis Bio Inc.)|Net Sales Margin TRACON Pharmaceuticals Inc. (TCON)|Net Margin Unity Bio UBX